Phaseline

Companies › SOTIO Biotech

SOTIO Biotech: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SOT201
CAR-T cell therapy
–Phase 1Advanced Solid TumorDec 2026
SOT109
CDH17-directed antibody-drug conjugate with exatecan payload
CDH17Phase 1Colorectal Cancer (Locally Advanced or Metastatic)Nov 2027
BOXR1030
anti-GPC3 CAR-T cell therapy
GPC3Phase 1Hepatocellular CarcinomaDec 2042

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06163391SOT201Phase 1Advanced Solid TumorOncologyDec 2026
NCT07693751SOT109Phase 1Colorectal Cancer (Locally Advanced or Metastatic)OncologyNov 2027
NCT05120271BOXR1030Phase 1Hepatocellular CarcinomaOncologyDec 2042

Targets

CDH17 (1) GPC3 (1)

Companies with the same targets

Chimeric Therapeutics AstraZeneca Keymed Biosciences Co.Ltd Newish Technology (Beijing) Aptamer Sciences Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Zymeworks BC RayzeBio Bayer BeOne Medicines

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.